3-chlorophenyl propargyl ether | 33302-52-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-chlorophenyl propargyl ether
• 英文别名: 1-chloro-3-(prop-2-ynyloxy)benzene；1-Chloro-3-(prop-2-yn-1-yloxy)benzene；1-chloro-3-prop-2-ynoxybenzene
• CAS: 33302-52-2
• 化学式: C₉H₇ClO
• mdl: MFCD14631205
• 分子量: 166.607
• InChiKey: MWRDOGDGBQFLTG-UHFFFAOYSA-N

物化性质

• 沸点：
  75-76 °C(Press: 3 Torr)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chlorophenyl propargyl ether 在 copper(l) iodide 、 trans-bis(triphenylphosphine)palladium dichloride 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 20.0 ℃ 、250.0 kPa 条件下， 生成 2,6-Bis[3-(3-chlorophenoxy)propyl]-1-methylpyridin-1-ium;trifluoromethanesulfonate
  参考文献：
  名称：

  Strategies To Reduce hERG K⁺Channel Blockade. Exploring Heteroaromaticity and Rigidity in Novel Pyridine Analogues of Dofetilide

  摘要：

  Drug-induced blockade of the human ether-a-go-go-related gene K+ channel (hERG) represents one of the major antitarget concerns in pharmaceutical industry. SAR studies of this ion channel have shed light on the structural requirements for hERG interaction but most importantly may reveal drug design principles to reduce hERG affinity. In the present study, a novel library of neutral and positively charged heteroaromatic derivatives of the class III antiarrhythmic agent dofetilide was synthesized and assessed for hERG affinity in radioligand binding and manual patch clamp assays. Structural modifications of the pyridine moiety, side chain, and peripheral aromatic moieties were evaluated, thereby revealing approaches for reducing hERG binding affinity. In particular, we found that the extra rigidity imposed close to the positively charged pyridine moiety can be very efficient in decreasing hERG affinity.

  DOI：

  10.1021/jm301564f
• 作为产物：
  描述：

  3-氯苯酚 、 对甲苯磺酸丙炔酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以63%的产率得到3-chlorophenyl propargyl ether
  参考文献：
  名称：

  1,4-Dihydroindeno[1,2-c]pyrazoles with Acetylenic Side Chains as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors with Low Affinity for the hERG Ion Channel

  摘要：

  The synthesis of a novel series of 1,4-dihydroindeno[1,2-c]pyrazoles with acetylene-type side chains is described. Optimization of those compounds as KDR kinase inhibitors identified 8, which displayed an oral activity in an estradiol-induced murine uterine edema model (ED50 = 3 mg/kg) superior to Sutent (ED50 = 9 mg/kg) and showed potent antitumor efficacy in an MX-1 human breast carcinoma xenograft tumor growth model (tumor growth inhibition = 90% at 25 mg/kg.day po). The compound was docked into a homology model of the homo-tetrameric pore domain of the hERG potassium channel to identify strategies to improve its cardiac safety profile. Systematic interruption of key binding interactions between 8 and Phe656, Tyr652, and Ser624 yielded 90, which only showed an IC50 of 11.6 mu M in the hERG patch clamp assay. The selectivity profile for 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with low nanomolar potencies against the members of the VEGFR and PDGFR kinase subfamilies.

  DOI：

  10.1021/jm061223o

文献信息

• 1,2,3-Triazole-based kojic acid analogs as potent tyrosinase inhibitors: Design, synthesis and biological evaluation
  作者：Morteza Ashooriha、Mehdi Khoshneviszadeh、Mahsima Khoshneviszadeh、Seyed Ershad Moradi、Alireza Rafiei、Mostafa Kardan、Saeed Emami

  DOI：10.1016/j.bioorg.2018.10.069

  日期：2019.2

  modifying primary alcoholic group of kojic acid as tyrosinase inhibitors. The target compounds 6a-p were synthesized via click reaction. All compounds showed very potent anti-tyrosinase activity (IC50s = 0.06–6.80 µM), being superior to reference drug, kojic acid. In particular, the naphthyloxy analogs 6o and 6p were found to be 31–155 times more potent than kojic acid. The metal-binding study of selected

  通过修饰曲酸的伯醇基作为酪氨酸酶抑制剂，设计了一系列带有芳氧基甲基-1 H -1,2,3-三唑-1-基部分的曲酸衍生的化合物6a-p。通过点击反应合成目标化合物6a-p。所有化合物均显示出非常有效的抗酪氨酸酶活性（IC 50 s = 0.06-6.80 µM），优于参考药物曲酸。特别是，萘氧基类似物6o和6p的效价比曲酸高31–155倍。所选化合物6o的金属结合研究表明，原型化合物具有金属螯合能力，尤其是对Cu 2+具有螯合能力。离子。如通过针对黑色素瘤（B16）细胞系和人包皮成纤维细胞（HFF）细胞的细胞毒性试验所证实的，有前途的化合物6o和6p具有可接受的安全性。
• [EN] HISTONE DEMENTHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014164708A1

  公开（公告）日：2014-10-09

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代吡咯吡啶衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物对组蛋白去甲基化酶的抑制具有用处。此外，所述化合物和组合物对癌症的治疗具有用处，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• 16-Substituted polyunsaturated hexadecanoic fatty acids
  申请人：Syntex (U.S.A.) Inc.

  公开号：US04867915A1

  公开（公告）日：1989-09-19

  Sixteen carbon atom carboxylic acids having 16-phenoxy or 16-phenylthio substituents, and 0, 1, or 4 triple bonds, methods of preparing them, and pharmaceutical preparations containing them. These compounds are useful as lipoxygenase inhibitors.

  含有16-苯氧基或16-苯硫基取代基的十六碳原子羧酸，以及0、1或4个三键的制备方法，以及含有它们的药物制剂。这些化合物可用作脂氧酶抑制剂。
• [EN] COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE<br/>[FR] COMPOSES, PROCEDES ET PREPARATIONS DESTINES A L'APPORT ORAL D'UN COMPOSE PEPTIDIQUE DE TYPE GLUCAGON (GLP-1) OU D'UN PEPTIDE AGONISTE DU RECEPTEUR 4 DE MELANOCORTINE (MC4)
  申请人：LILLY CO ELI

  公开号：WO2005019184A1

  公开（公告）日：2005-03-03

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及用于口服给荷GLP-1化合物或MC4激动剂肽的新化合物、方法和配方。
• Synthesis of Organochalcogen Propargyl Aryl Ethers and Their Application in the Electrophilic Cyclization Reaction: An Efficient Preparation of 3-Halo-4-Chalcogen-2<i>H</i>-Benzopyrans
  作者：Benhur Godoi、Adriane Sperança、Davi F. Back、Ricardo Brandão、Cristina W. Nogueira、Gilson Zeni

  DOI：10.1021/jo900307k

  日期：2009.5.1

  atom of the electrophilic chalcogen species. Additional versatility in this process was demonstrated with respect to a diverse array of functionality in the aromatic ring at propargyl aryl ethers. These propargyl aryl ethers, bearing the chalcogen group, underwent highly selective intramolecular cyclizations when treated with I2 or ICl affording 3-iodo-4-chalcogen-2H-benzopyrans. The results demonstrated

  我们在本文中描述了通过乙炔化锂中间体与亲电子硫属元素（硫，硒，碲）物质的反应来合成各种有机硫属炔丙基芳基醚。直接与硫属元素原子键合的各种芳基和烷基用作亲电子试剂。结果表明，该反应不显着取决于键合至亲电子硫属元素物种的硫属元素原子上的芳环中取代基的电子效应。关于炔丙基芳基醚在芳环中的多种官能团，证明了该方法的其他通用性。这些带有硫属元素基的炔丙基芳基醚在经过I 2处理后经历了高度选择性的分子内环化反应或ICl得到3-碘-4-硫属元素-2H-苯并吡喃。结果表明，环化效率受芳环的空间效应的显着影响，这是因为环化反应在orto位置具有取代基的芳环比没有取代基的芳环的收率低。还研究了3-碘-4-硫属元素-2H-苯并吡喃的反应性。在Neghishi交叉偶联条件下处理4-硒代丁基苯并吡喃，以良好的收率提供相应的3-芳基苯并吡喃衍生物。另外，在没有任何助催化剂的情况下，使用铜催化的与硫醇的交叉偶联反应，我